OncoGenesis Inc.

OncoGenesis addresses the tremendous, unmet clinical need for an easy to use and accurate screening of women for cervical cancer. The company offers a comprehensive solution ranging from optimal specimen collection to point-of-care diagnostic testing that will set a new standard of care for diagnosing and treating cervical cancer worldwide.

Our goal is to provide a solution that clinically outperforms existing screening technologies in a cost-effective format that can be run anywhere globally – including resource-limited regions of the world where the problem of cervical cancer is a healthcare crisis.

To accomplish this, OncoGenesis has developed a useful self-collection device, iPap™, that allows women to obtain their cervical specimens in the privacy of their home. The company is also developing the CerMark™ multiplex biomarker test that measures the critical cellular changes in a cervical tissue specimen. By measuring these markers, the test detects cervical cancer, disease progression, and its aggressiveness. The CerMark test will be available first on a laboratory-based system (LAB) and then on our Point-of-Care (POC) device.

Company’s Keywords:

cervical cancer screening